Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...
Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis[1] Approximately 22 million women in US have osteopenia, ...
Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.
EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...
The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...
The FDA has approved Reclast (zoledronic acid, from Novartis) injection for the prevention of osteoporosis in women for two years with a single dose. This approval was based on a study involving more ...
EAST HANOVER, N.J., Oct. 16 Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in postmenopausal ...
June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: For the last few years, I have been taking yearly Reclast ...
A simple annual infusion of a new drug is just as effective at reducing bone fractures as weekly or monthly bone loss drugs currently on the market, according to a study by researchers at the ...
Discover more of our free reports coverage from other companies within the Drugs - Generic industry. Pro-TD has currently selected Allergan PLC (NYSE: AGN) for due-diligence and potential coverage as ...
EAST HANOVER, N.J., April 11 New data show that aonce-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg wassignificantly better than risedronate at increasing bone mass in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback